IP Verse

Formulations Of (R - EP3509581

The patent EP3509581 was granted to Axsome Malta on Nov 9, 2022. The application was originally filed on Sep 6, 2017 under application number EP17849426A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3509581

AXSOME MALTA
Application Number
EP17849426A
Filing Date
Sep 6, 2017
Status
Granted And Under Opposition
Oct 7, 2022
Grant Date
Nov 9, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZAug 8, 2023ADMISSIBLE

Patent Citations (32) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2012004300
DESCRIPTIONUS2015018414
DESCRIPTIONUS5705640
DESCRIPTIONUS5756817
DESCRIPTIONUS5955499
DESCRIPTIONUS6140532
DESCRIPTIONUS6680299
DESCRIPTIONUS6680322
DESCRIPTIONUS6680324
DESCRIPTIONUS8232315
DESCRIPTIONUS8440715
DESCRIPTIONUS8552060
DESCRIPTIONUS8623913
DESCRIPTIONUS8729120
DESCRIPTIONUS8741950
DESCRIPTIONUS8895609
DESCRIPTIONUS8927602
DESCRIPTIONUS8952062
DESCRIPTIONUS9050302
DESCRIPTIONUS9226910
DESCRIPTIONUS9359290
INTERNATIONAL-SEARCH-REPORTUS2011111027
INTERNATIONAL-SEARCH-REPORTUS2014350098
INTERNATIONAL-SEARCH-REPORTUS2015246874
INTERNATIONAL-SEARCH-REPORTUS2016081970
OPPOSITIONUS2011111027
OPPOSITIONUS2014275244
OPPOSITIONWO2006133393
SEARCHUS2012004300
SEARCHUS2015018414
SEARCHUS5955499
SEARCHWO2008048801

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- REMINGTON, Oral Solid Dosage Forms-
DESCRIPTION- T. HIGUCHIV. STELLA, "Prodrugs as Novel delivery Systems", A.C.S. Symposium Series, vol. 14-
OPPOSITION- Anonymous, "Assessment report - Sunosi - International non-proprietary name: solriamfetol", European Medicines Agency; Procedure No. EMEA/H/C/004893/0000; EMA/686622/2019 Committee for Medicinal Products for Human Use (CHMP), (20191114), European Medicines Agency; Procedure No. EMEA/H/C/004893/0000; EMA/686622/2019 Committee for Medicinal Products for Human Use (CHMP), XP093182204-
OPPOSITION- Anonymous, "Joint Supervisory Review of Sunosi / solriamfetol", U.S. FOOD AND DRUGS ADMINISTRATION; CENTER FOR DRUG EVALUATION AND RESEARCH, (20190320), U.S. FOOD AND DRUGS ADMINISTRATION; CENTER FOR DRUG EVALUATION AND RESEARCH, XP093182206-
OPPOSITION- Gilbert S Banker , Neil R Anderson, "Tablets", Gilbert S Banker , Neil R Anderson, Leon Lachman , Herbert A Lieberman , Joseph L Kanig, The Theory and Practice Of Industrial Pharmacy Third edition, Dadar Bombay, Varghese Publishing House, (19870101), pages 393 - 394, XP093161674-
OPPOSITION- Göran Alderborn, "Chapter 27: Dosage from design and manufacture ", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier , (20020101), pages 397 - 438, ISBN 0-443-05517-3, XP009555454-
OPPOSITION- "Guidance for industry - Dissolution testing of immediate release solid oral dosageforms", PUBLICATION OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, XX, XX, XX , (19970801), pages 1 - 14, XP002980390-
OPPOSITION- James Wells, "Chapter 8: Pharmaceutical preformulation: the physicochemical properties of drug substances.", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier , (20020101), pages 113 - 138, ISBN 0-443-05517-3, XP009555452-
OPPOSITION- Peter York, "Chapter 1: The design of dosage forms", Peter York, Michael E. Aulton, PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier , (20020101), pages 1 - 12, ISBN 0-443-05517-3, XP009555448-
OPPOSITION- Tsume Yasuhiro; Mudie Deanna M.; Langguth Peter; Amidon Greg E.; Amidon Gordon L., "The Biopharmaceutics Classification System: Subclasses forin vivopredictive dissolution (IPD) methodology and IVIVC", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL , (20140128), vol. 57, doi:10.1016/j.ejps.2014.01.009, ISSN 0928-0987, pages 152 - 163, XP028648885
OPPOSITION- Shannon S Sullivan, Christian Guilleminault, "Emerging drugs for common conditions of sleepiness: obstructive sleep apnea and narcolepsy", EXPERT OPINION ON EMERGING DRUGS, Informa Healthcare, UK, UK , (20151002), vol. 20, no. 4, doi:10.1517/14728214.2015.1115480, ISSN 1472-8214, pages 571 - 582, XP055300177
OPPOSITION- Quinnell Timothy, Wozniak Dariusz, "Unmet needs of patients with narcolepsy: perspectives on emerging treatment options", Nature and Science of Sleep, Dove Medical Press, doi:10.2147/NSS.S56077, ISSN 1179-1608, page 51, XP093182199
SEARCH- AMSTERDAM JAY D ET AL, "A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A: a putative, new antidepressant", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, ELSEVIER, GB, vol. 26, no. 7-8, doi:10.1016/S0278-5846(02)00298-1, ISSN 0278-5846, (20021201), pages 1333 - 1338, (20021107), XP008166241 [A] 1-18 * abstract * * page 1334, column l, paragraph l - page 1334, column r, paragraph 2 * * page 1337, column r, paragraph l *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents